Uridine
6 benefits mapped to clinical evidence across supplements.
Dose per serving from research
6 study groups in 5 studies say how much Uridine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 33% of 6 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 1 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 2 |
| 1 g to 2.5 g | 0 |
| 2.5 g to 5 g | 0 |
| 5 g to 10 g | 0 |
| 10 g to 25 g | 0 |
| 25 g to 50 g | 0 |
| 50 g to 100 g | 0 |
| over 100 g | 1 |
Commonly used together
4 of 6 study groups took Uridine with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 4 |
Benefit Evidence
EEG preserved +0.015
Nerve symptoms improved
Conduction improved, unspecified
EEG preserved +0.015
Nerve symptoms improved
Conduction improved, unspecified
Research sources
Nerve health (9)
- [Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain]
PubMed ID: 40760891
Adding a nucleotide complex to lornoxicam improved pain/function/relapse in acute low back pain—supports nucleotide use for recovery/nerve-related function (composition not fully described).
- Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients
PubMed ID: 39683579
Randomized trial of oral pyrimidine nucleotides (uridine/cytidine) + B1/B12 showed modest functional and clinician-rated improvement in radiculopathy—direct evidence for peripheral nerve benefit.
- Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study
PubMed ID: 1325728
Direct randomized human study: oral uridine improved nerve conduction measures in diabetic peripheral neuropathy vs placebo (statistically significant changes by day 120).
- Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia
PubMed ID: 12834861
Brivudin (deoxyuridine analogue) reduced incidence of postherpetic neuralgia vs acyclovir in elderly—indirectly relevant to nerve outcomes.
- The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study
PubMed ID: 24475144
Souvenaid provides uridine (UMP) plus other precursors for phospholipid/synapse synthesis; trial data show preserved network metrics consistent with synaptic support.
- [Medicamentous therapy of alcoholic polyneuropathy. Randomized double-blind study comparing 2 vitamin B preparations and a nucleotide preparation]
PubMed ID: 9064269
Randomized trial: oral cytidine+uridine improved symptoms in alcoholic polyneuropathy—direct clinical evidence for peripheral nerve benefit.
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
PubMed ID: 26213579
Souvenaid markedly raised plasma uridine, choline and DHA — the combination (Fortasyn) was designed to supply substrates for synapse formation; biomarker evidence strongly supports substrate provision for synaptogenesis.
- The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?
PubMed ID: 31616139
Fortasyn Connect (uridine monophosphate among other substrates required for synaptogenesis) produced structural benefits (less hippocampal atrophy) and slowed clinical decline — aligns with synapse preservation/growth hypothesis.
- [Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study]
PubMed ID: 9035511
Randomized blinded trial of CMP/UTP/B12 improved gait and spasticity in progressive spastic paraparesis—direct neurologic benefit involving nucleotides including uridine triphosphate.
Illness recovery (4)
- [Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain]
PubMed ID: 40760891
Adding nucleotide complex to anti-inflammatory therapy improved pain and relapse rates in acute back pain, suggesting accelerated recovery.
- Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery
PubMed ID: 12637462
Large RCT showed adding cyclophosphamide to oral doxifluridine reduced recurrences (improved disease-free survival) — clinical outcome consistent with improved post-treatment recovery/recurrence prevention in oncology context.
- [Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study]
PubMed ID: 9035511
Randomized trial of CMP/UTP/B12 showed statistically significant clinical recovery (gait/spasticity) vs placebo—direct evidence of accelerated recovery.
- Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients
PubMed ID: 39683579
Supplementation with uridine/cytidine + B vitamins led to better functional recovery in radiculopathy vs control—direct clinical signal for faster recovery.
Healthy aging (3)
- The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?
PubMed ID: 31616139
2‑year Fortasyn Connect (contains uridine) slowed clinical decline (CDR‑SB) and reduced hippocampal atrophy in prodromal AD — signal for slowing age‑related cognitive decline.
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
PubMed ID: 26213579
Souvenaid/Fortasyn increased plasma uridine, choline and DHA — nutrients implicated in maintaining neuronal membranes and may support brain health with aging (biomarker evidence).
- The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study
PubMed ID: 24475144
Souvenaid (contains uridine monophosphate) preserved EEG network organization in mild AD over 24 weeks—suggests a neuroprotective effect relevant to aging brain.
Cell health (2)
- Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
PubMed ID: 26213579
Direct biochemical evidence: Souvenaid/Fortasyn markedly increases plasma uridine, choline and DHA — key substrates for neuronal phospholipid (membrane) synthesis.
- The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study
PubMed ID: 24475144
Souvenaid contains uridine (UMP), intended to support phospholipid membrane synthesis; trial outcomes are consistent with preserved neural network structure.
Learning (1)
- The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study
PubMed ID: 24475144
Preserved EEG network organization in Souvenaid‑treated mild AD patients suggests maintained functional network adaptability; direct neurophysiological evidence.
Memory (1)
- The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study
PubMed ID: 24475144
Souvenaid (contains uridine monophosphate) has randomized‑trial evidence of improved memory and preserved EEG network properties in mild AD—direct clinical evidence.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Uridine
Search all72 products whose verified label declares Uridine — not every bottle that mentions it in a title.